Interleukin 7: all 25 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)RecruitingNCT07308886Phase 2
- Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedNCT03513952Phase 2Results posted
- A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis PatientsCompletedNCT02640807Phase 2Results posted
- CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01881867Phase 2Results posted
- Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had ChemotherapyTerminatedNCT01339000Phase 2Results posted
- Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or NeuroblastomaCompletedNCT00923351Phase 1/2Results posted
- Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)TerminatedNCT00839436Phase 1/2Results posted
- Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell TransplantActive, not recruitingNCT06523699Phase 1
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)TerminatedNCT04927169Phase 2
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )TerminatedNCT04442178Phase 2
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )TerminatedNCT04426201Phase 2
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL CohortTerminatedNCT04407689Phase 2
- InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK CohortTerminatedNCT04379076Phase 2
- Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis PatientsTerminatedNCT03821038Phase 2
- Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood TransplantationWithdrawnNCT03600896Phase 1/2
- Immune Reconstitution of Immunosuppressed Sepsis PatientsTerminatedNCT02797431Phase 2
- Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer PatientsCompletedNCT01368107Phase 2
- Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-respondersTerminatedNCT01241643Phase 2
- Study on Interleukin-7 (CYT107) in HIV PatientsTerminatedNCT01190111Phase 2
- Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)CompletedNCT01025596Phase 1/2
- Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy AloneStatus unknownNCT01025297Phase 1/2
- Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to BitherapyStatus unknownNCT01024894Phase 1/2
- Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell TransplantCompletedNCT00684008Phase 1
- Safety Study of IL-7 in HIV-infected Patients (Inspire)CompletedNCT00477321Phase 1
- Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral TreatmentCompletedNCT00105417Phase 1